IQ-AI Limited has opened its Phase I clinical trial for oral gallium maltolate (GaM) for enrolment.
The trial is being led by Dr Jennifer Connelly, MD, Associate Professor of Neurology, and Dr Christopher Chitambar, MD, Emeritus Professor of Medicine and Biophysics, Division of Hematology and Oncology, both at the Medical College of Wisconsin (MCW).
"Patient recruitment in the trial is underway and potential volunteers that meet the inclusion criteria have already been identified," said a statement.
“This Phase I dose-escalation study is designed to determine the optimal dose of GaM that can be administered safely,” the company added.
It is the first-in-human clinical trial for an oral form of GaM to be used in patients with high-grade brain tumours.
"I applaud the efforts of everyone involved in qualifying a new encapsulation supplier and preparing the necessary documentation to the FDA, and that the start of this much-anticipated trial is now finally underway," said Trevor Brown, IQ-AI.s chief executive.
IQ-AI had to reschedule the trial after a change to the trial agent's encapsulation supplier.
The study will assess the potential of Gallium Maltolate to treat Glioblastoma Multiforme, the most common brain tumour.